Related Experiment Video
Updated: Jun 27, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune
Yifei Ma1, Jiling Zeng2,3, Fadian Ding1
1Department of Hepatobiliary and Pancreatic Surgery, Institute of Abdominal Surgery, Fujian Provincial Key Laboratory of Precision Medicine for Cancer, and Department of Hepatobiliary and Pancreatic Surgery, National Regional Medical Center Binhai Campus, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Abstract:
Our aim was to investigate probable biomarkers specific to immune-related central nervous system toxicity (CNST) in cancer patients treated with immune checkpoint inhibitors (ICI) by analysis of 18F-FDG PET/CT images. Methods: Cancer patients receiving ICI treatment were enrolled in a multicenter observational study that analyzed regional metabolic changes before and during CNST onset from January 2020 to February 2022. In 1:1 propensity score-matched pairs, the regional SUVmean of each bilateral brain lobe of CNST patients (CNST+) was compared with that of patients who had central nervous system infections (CNSIs) and patients without CNST or CNSI (CNST-). In a validation cohort, patients were recruited from February 2022 to July 2023 and followed up for 24 wk after the start of ICI. Early changes in regional SUVmean at 5-6 wk after therapy initiation were evaluated for ability to predict later CNST onset. Results: Of 6,395 ICI-treated patients, 2,387 underwent prognostic 18F-FDG PET/CT and 125 of the scanned patients had CNST (median time from ICI treatment to onset, 9 wk; quartile range, 2-23 wk). Regional 18F-FDG PET/CT SUVmean changes were higher in CNST+ than in CNST- patients (117 patient pairs) but were lower than in CNSI patients (50 pairs). Differentiating analysis reached an area under the curve (AUC) of 0.83 (95% CI, 0.78-0.88) for CNST+ versus CNST- and of 0.80 (95% CI, 0.72-0.89) for CNST+ versus CNSI. Changes in SUVmean were also higher before CNST onset than for CNST- (60 pairs; AUC, 0.74; 95% CI, 0.66-0.83). In a validation cohort of 2,878 patients, preonset changes in SUVmean reached an AUC of 0.86 (95% CI, 0.79-0.94) in predicting later CNST incidence. Conclusion: Brain regional hypermetabolism could be detected during and before CNST clinical onset. CNST may be a distinct pathologic entity versus brain infections defined by 18F-FDG PET/CT brain scans. Regional SUV differences may be translated into early diagnostic tools based on moderate differentiating accuracy in our study.
Insights
Immune checkpoint inhibitors (ICI) can cause central nervous system toxicity (CNST). 18F-FDG PET/CT scans detect brain hypermetabolism before and during CNST onset, aiding early diagnosis in cancer patients.
Area of Science:
- Neuro-oncology
- Nuclear Medicine
- Radiology
Background:
- Immune checkpoint inhibitors (ICI) are crucial in cancer therapy but can cause immune-related central nervous system toxicity (CNST).
- Early identification of CNST is challenging, necessitating reliable biomarkers.
- 18F-FDG PET/CT imaging offers a potential tool for assessing brain metabolic changes.
Purpose of the Study:
- To identify potential biomarkers for ICI-related CNST using 18F-FDG PET/CT.
- To differentiate CNST from central nervous system infections (CNSIs) and from no neurological events.
- To evaluate the predictive value of early metabolic changes for later CNST onset.
Main Methods:
- A multicenter observational study analyzed 18F-FDG PET/CT scans in cancer patients treated with ICI.
- Regional SUVmean changes in brain lobes were compared between CNST+ patients, CNST- patients, and CNSIs patients using propensity score matching.
- A validation cohort assessed early metabolic changes (5-6 weeks post-therapy) for predicting CNST incidence.
Main Results:
- 18F-FDG PET/CT identified higher regional SUVmean changes in CNST+ versus CNST- patients (AUC 0.83) and CNSI patients (AUC 0.80).
- Metabolic changes were detectable before CNST onset (AUC 0.74 for CNST+ vs. CNST-).
- In the validation cohort, early metabolic changes predicted later CNST incidence (AUC 0.86).
Conclusions:
- Brain regional hypermetabolism is detectable before and during clinical onset of ICI-related CNST.
- 18F-FDG PET/CT findings suggest CNST is a distinct entity from brain infections.
- Regional metabolic differences show potential for developing early diagnostic tools for CNST.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET